- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01258816
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
A Phase I Study of the Human Pharmacokinetics and Cardiac Safety of Elacytarabine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Elacytarabine is an investigational drug which is not commercially available. It consists of a fatty acid that is connected to cytarabine which is commonly used in treatment of AML. Due to the connection to a fatty acid, elacytarabine might have an increased uptake in blast cells and thereby increased efficacy.
The characterisation of the pharmacokinetics of an investigational drug, as well as the cardiac safety are essential. The PK of both elacytarabine and its metabolites will be assessed at defined timepoints before, during and after infusion. The cardiac safety of elacytarabine will be evaluated by triplicate ECG recordings at the same time points as the PK assessments.
Elacytarabine will be given as a continuous infusion for 5 days. The patients may continue with further courses of elacytarabine as long as the patient benefits from treatment with elacytarabine.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08035
- Hospital General de la Vall d' Hebron
-
Cáceres, Spain, 10003
- Hospital San Pedro Alcántara
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08907
- ICO - Hospital Duran i Reynals
-
-
-
-
-
Brighton, United Kingdom, BN2 5BE
- Brighton & Sussex University Hospitals NHS Trust
-
Cardiff, United Kingdom, CF14 4XW
- University Hospital of Wales, Cardiff
-
London, United Kingdom, EC1A 7BE
- St Bartholomew's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion¨Criteria:
- Patients must have relapsed / refractory AML according to WHO classification (excluding acute promyelocytic leukaemia)
- Patients must have ECOG Performance Status (PS) of 0 - 2
- Patients must be 18 years of age or older
- Women of child-bearing potential must have a negative serum or urine pregnancy test within two weeks prior to treatment start
- Male and female fertile patients must use adequate contraception for the duration of the study, and males also for 3 months after the last elacytarabine dose
- Patients must be capable of understanding and complying with protocol requirements, and they must be able and willing to sign a written informed consent
Exclusion Criteria:
- A history of allergic reactions to egg. A history of CTCAE grade 3 or 4 allergic reactions to ara-C of
- A history of cancer that according to the investigator might confound the assessment of the endpoints of the clinical study
- Known positive status for human immunodeficiency virus (HIV)
- Pregnant and nursing patients
- Uncontrolled inter-current illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that will limit compliance with study requirements
- Impairment of hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into the clinical study
- Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medications, or uncontrolled congestive heart failure. Any NYHA grade 3 or 4
- A history of familial long QT syndrome
- Patients with history of serious ventricular arrhythmia (VT or VT)
- ECG criteria at the eligibility visit: QTc ≥ 480 msec calculated using Fridericia's correction (QTcF = QT/RRO,33) or bradycardia (<50bpm) or criteria for left ventricular hypertrophy
- treatment with any medications known to produce QT prolongations
- Treatment with hydroxyurea or 6-mercaptopurine within the last 12 hours prior to treatment on this protocol or any other investigational or standard cytotoxic treatment within the last 14 days
9. Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterise the pharmacokinetics of elacytarabine in patients with relapsed/refractory Acute Myeloid Leukaemia
Time Frame: During first week of treatment course
|
Collection of pheripheral blood samples at specified time points during first week of the treatment course for PK analyses
|
During first week of treatment course
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigate the activity of elacytarabine measured as remission rate (CR + CRi)
Time Frame: After each course
|
Bone marrow and/or blood examination
|
After each course
|
Number of patients with Adverse Events as a measure of safety and tolerability
Time Frame: Continuously during study
|
Continuously during study
|
|
Evaluate the cardiac safety of elacytarabine with focus on the QT/QTc intervals
Time Frame: During the first week of treatment
|
Triplicate 12-lead ECG assessments will be done at specified time points before, during and after infusion
|
During the first week of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven Knapper, MD, Cardiff University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CP4055-109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory AML
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
Apollomics Inc.Zhejiang CrownMab Biotech Co. LtdRecruitingRelapsed/Refractory AMLChina
-
Fujian Medical UniversityUnknown
-
Apollomics Inc.Zhejiang CrownMab Biotech Co. LtdRecruitingRelapsed/Refractory AMLChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...Recruiting
-
Seattle Children's HospitalChildren's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...CompletedAML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDSUnited States, Canada
-
The Affiliated Hospital of the Chinese Academy...Chinese PLA General HospitalUnknown
-
The First Affiliated Hospital of Soochow UniversityNot yet recruitingRelapsed/Refractory AMLChina
Clinical Trials on Elacytarabine for infusion
-
Aro BiotherapeuticsRecruiting
-
AstraZenecaCompletedChronic PainGermany, Sweden, United Kingdom
-
Clavis PharmaCompletedAcute Myeloid Leukemia (AML)United States, Spain, France, Ireland, United Kingdom, Australia, Belgium, Canada, Germany, Italy, Norway, Poland, Romania
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedPrimary Sjögren's SyndromeUnited States, France, United Kingdom, Australia, Germany, Hungary, Spain
-
Assaf-Harofeh Medical CenterNot yet recruiting
-
Clavis PharmaCompletedNot Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy SubjectsUnited Kingdom
-
Pinteon Therapeutics, IncUnited States Department of DefenseTerminatedTraumatic Brain InjuryUnited States
-
PharmaMarCompletedAcute LeukemiaUnited States
-
TakedaTakeda Development Center Americas, Inc.Active, not recruitingHunter SyndromeUnited States, Germany, Malaysia, Philippines, Thailand, Dominican Republic, Serbia, Vietnam
-
Yonsei UniversityCompleted